The company plans to be a leader in the production, formulation and clinical development of muscle relaxation molecules derived from microalgae. Phytotox expects to commercialize its products for several pharmaceuticals indications through licensing, partnerships or direct sales. To this end the company is preparing an IND package for injectable pharmaceutical applications. This includes product manufacturing and controls, preclinical animal studies and the corresponding clinical program (this last will be designed by or in collaboration with a licensee company). In addittion, an active ingredient for cosmetic applications is under way by our european subsidiary.
| Website | http://www.phytotox.com |
| Revenue | $2.6 million |
| Employees | 7 (2 on RocketReach) |
| Technologies | |
| Industry | Biotechnology Research |
| Keywords | Muscle Relaxation, Microalgae Extracts, Pharmaceutical Ingredients, Biotechnology, Drug Development, Clinical Trials, Innovative Therapies, Licensing Agreements, Research And Development, Scientific Innovation, Bioactive Compounds, Pharmaceutical Production, Drug Discovery, Health And Wellness, Alternative Medicine, Plant Based Medicine, Sustainable Solutions |
| Competitors | Dow, Syngenta, Corteva Agriscience, Nutrien, FMC Corporation, ADAMA Ltd., Bayer, Valent U.S.A. LLC, AgroFresh, Upl Limited (Formerly Known as United Phosphorus Ltd.) +32 more (view full list) |
Looking for a particular Phytotox employee's phone or email?
Phytotox Questions
The Phytotox annual revenue was $2.6 million in 2026.
Jean Pilorget is the Director I and D of Phytotox.
2 people are employed at Phytotox.
Top Phytotox Employees
